drugset

drugset / Trial / NCT00193713

Bifeprunox in the Treatment of Schizophrenia

NCT00193713 ↗

Phase 3 Completed Solvay Pharmaceuticals

RandomizedParallel-groupDouble-blindTreatment

Summary

Study of the long-term efficacy and safety of bifeprunox in the treatment of schizophrenia.

Timeline

Start: 2005-05
Primary completion: 2006-11
Completion: 2006-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bifeprunox	Small molecule	—	—

Indications